Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

NCT07141472 | Completed

• 1 other identifier: AB20241210H
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).

Conditions

Blood Sugar; High; Overweight and Obesity; Fat Loss; GLP-1; Glucagon

Keywords

GLP-1; blood glucose; HbA1c; insulin; glucagon; GIP; Amylin

Outcome Measures

Primary Outcomes (10)

• fasting blood HbA1c level

  lab

  26 weeks

• fasting blood glucose level

  lab

  26 weeks

• fasting blood insulin level

  lab

  26 weeks

• fasting blood GLP-1 level

  lab

  26 week

• fasting blood glucagon level

  lab

  26 weeks

• fasting blood GIP level

  lab

  26 weeks

• fasting blood Amylin level

  lab

  26 weeks

• fasting body weight

  measurement

  26 weeks

• body fat mass

  measurement

  26 week

• waist hip ratio

  measurement

  26 weeks

Secondary Outcomes (5)

• satiety score

  26 weeks

• resting metabolic rate

  26 weeks

• Blood pressure

  26 weeks

• Heart rate

  26 weeks

• Energy level

  26 weeks

Study Arms (2)

Active Group who take GB

EXPERIMENTAL

GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.

Dietary Supplement: GB

Placebo Group

PLACEBO COMPARATOR

Placebo is a product that resemble Active product but does not contain any of the active ingredients.

Dietary Supplement: Placebo

Interventions

GB DIETARY_SUPPLEMENT

GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.

Active Group who take GB

Placebo DIETARY_SUPPLEMENT

Placebo is a product that resemble active GB but does not contain any of the active ingredients

Placebo Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteers must be over the age of 18.
• Volunteers cannot be smokers.
• Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
• Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
• Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
• Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9

Sponsors & Collaborators

• Lawry Han: lead

Study Sites (1)

Alpine Bio

Salt Lake City, Utah, 84108, United States

Location

MeSH Terms

Conditions

Hyperglycemia; Overweight; Obesity; Insulin Resistance

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism

Study Officials

• Lawry Han, PhD

  Alpine Biotech

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Model Details: RCT

Study Record Dates

• First Submitted: August 19, 2025
• First Posted: August 26, 2025
• Study Start: January 7, 2025
• Primary Completion: July 15, 2025
• Study Completion: August 14, 2025
• Last Updated: September 3, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)